Abstract
Background and Aim
This study aimed to evaluate the clinical outcomes following the discontinuation of nucleos(t)ide analogue (NA) treatment in hepatitis B e antigen (HBeAg)-negative patients with chronic hepatitis B (CHB).
Materials and Methods
This single-center retrospective cohort study included 146 non-cirrhotic patients with CHB who achieved long-term viral suppression under NA treatment. Seventy-three patients discontinued NA treatment, while a historical age- and sex-matched control group consisted of 73 patients who continued NA treatment.
Results
Hepatitis B surface antigen (HBsAg) seroclearance occurred in eight patients (11%) in the treatment-discontinuation group, while none was observed in the treatment-continued group (p = 0.004). The cumulative probability of HBsAg loss was 16.9% at month 120 after NA discontinuation. Firth-penalized Cox regression analysis identified younger age (<50 years) at treatment discontinuation (p=0.023) and elevated baseline serum AST levels (p=0.018) as independent predictors of HBsAg seroclearance. Seventy-five percent of these patients experienced HBsAg seroconversion to hepatitis B surface antibody (anti-HBs). After NA discontinuation, 67% of the patients (49/73) in the treatment-discontinuation group experienced virological relapse. Of these, 29 developed clinical relapse and reinitiated antiviral treatment, while the remaining 20 patients continued follow-up without antiviral therapy. Most clinical relapses (72%) occurred within the first 3 months after treatment discontinuation. Virological relapse did not occur in the other 24 patients. Overall, 44 patients in the treatment-discontinuation group (60%) did not require retreatment during follow-up.
Conclusion
Discontinuation of long-term NA treatment in selected HBeAg-negative patients was associated with HBsAg seroclearance and may contribute to a functional cure. Close post-discontinuation surveillance remains essential for early detection and management of clinical relapse.
Keywords: Antiviral therapy discontinuation, HBsAg Seroclearance, Hepatitis B virus
Highlights & Insights
Scientific Gap: HBsAg seroclearance is rare during long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B, and data on outcomes after treatment discontinuation are scarce and heterogeneous.
Key Finding: HBsAg seroclearance occurred in 11.0% of patients after nucleos(t)ide analogue discontinuation and in none of those who continued treatment; 75% of these patients developed anti-HBs. Clinical relapse occurred in 39.7%, mostly within the first 3 months.
Clinical Impact: Nucleos(t)ide analogue discontinuation may increase the likelihood of functional cure in carefully selected non-cirrhotic, HBeAg-negative patients, provided that close post-treatment monitoring is ensured.
Introduction
Chronic hepatitis B virus (HBV) infection continues to pose a significant public health concern globally, affecting approximately 250 million individuals.[1,2] HBV accounts for most adult cases of cirrhosis and hepatocellular carcinoma (HCC) in Türkiye.[3–5] A 2009 epidemiological study found that the prevalence of hepatitis B surface antigen (HBsAg) was approximately 4%, with more than 2 million adults testing positive for HBsAg in Türkiye.[6]
Nucleos(t)ide analog (NA) antiviral therapy provides effective long-term viral suppression and mitigates disease progression in patients with chronic hepatitis B (CHB). The primary goal of antiviral treatment for HBV is to eliminate HBsAg and achieve seroconversion to hepatitis B surface antibody (anti-HBs). Unfortunately, HBsAg seroclearance rarely occurs after long-term NA treatment with current antiviral therapies.[2,7] HBsAg loss was observed in approximately 10% of patients with hepatitis B e antigen (HBeAg)-positive and around 1% of HBeAg-negative patients after 8 years of tenofovir disoproxil fumarate (TDF) treatment.[8,9] Consequently, many patients with HBeAg-negative require indefinite therapy, which presents challenges related to adherence, cumulative drug exposure, and potentially side effects, antiviral resistance, and long-term healthcare costs.[2,7,10] Emerging evidence from randomized trials and real-world studies has reignited interest in discontinuing NA therapy to stimulate host immune responses that may lead to HBsAg seroclearance.[11–13]
According to previous studies, NA treatment may be discontinued in selected patients with CHB.[7,12–14] In some cases, discontinuation of NA treatment can lead to a functional cure by triggering immune control.[12–16] However, the data are heterogeneous and scarce. Additionally, previous studies do not clearly define the characteristics of the selected patients. In this single-center study, we examined the clinical outcomes of NA discontinuation in a rigorously selected cohort of non-cirrhotic, HBeAg-negative patients with CHB.
Materials and Methods
Study Design and Patient Population
This is a retrospective, single-center observational cohort study conducted at the Liver Diseases Outpatient Clinic. Chronic HBV infection was diagnosed and treated based on the European Association for the Study of the Liver guideline.[7] A total of 852 patients with CHB who were followed at our center between January 2014 and December 2024 were screened for eligibility. The study protocol was approved by the Ankara University Faculty of Medicine Human Research Ethics Committee (approval number: 2025/393, date: 22/05/2025) and was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants.
Patient Selection, Study Groups, and Monitoring Protocol
All patients in the screened cohort were evaluated using the same eligibility and exclusion criteria before being classified by treatment status. Eligible patients were adults with non-cirrhotic, HBeAg-negative CHB who had received licensed oral NA for at least 5 years, maintained virological suppression, defined as undetectable serum HBV DNA, for at least 3 years before the index date, and had normal serum ALT levels. Patients with cirrhosis, a history of hepatic decompensation, liver stiffness greater than 10 kPa, hepatocellular carcinoma, viral coinfection, another concomitant liver disease, or insufficient clinical follow-up were excluded. The discontinuation of NA treatment was conducted in accordance with local regulations. Of the 477 eligible patients, 73 had discontinued NA treatment, and 404 had continued treatment. Propensity scores based on age and sex were used for 1:1 matching without replacement. Each patient in the discontinuation group was matched to one patient in the continuation group with a maximum absolute propensity score difference of 0.01. The final matched cohort included 146 patients: 73 in the NA-discontinuation group and 73 in the NA-continuation group. The index date was defined as the NA discontinuation date for the discontinuation group and the corresponding cohort-entry date for the matched continuation group. The patient-selection process is presented in Figure 1.
Figure 1.

Flowchart illustrating patient selection and propensity score matching.
Laboratory Measurements
Laboratory parameters, including serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), bilirubin, and complete blood cell counts, were measured at baseline and during follow-up using standard automated methods in our institution’s central laboratory. Baseline laboratory values were those obtained immediately before initiation of NA treatment. Histological activity and fibrosis stage were based on the pretreatment liver biopsy. Quantitative HBsAg at NA discontinuation was measured using the Elecsys HBsAg II Quant assay (Roche Diagnostics, Mannheim, Germany). Serum HBV DNA levels were assessed using the Cobas TaqMan assay (Roche Diagnostics, Branchburg, NJ, USA) with a lower limit of detection of 20 IU/mL.
Definitions and Study Endpoints
The primary endpoints of the study were to investigate sustained HBsAg seroclearance and to identify factors associated with seroclearance. HBsAg seroclearance was defined as the loss of detectable HBsAg for at least six months, with or without seroconversion to anti-HBs following discontinuation of NA treatment. The secondary endpoints included virological, biochemical, and clinical relapse through the last follow-up. Virological relapse was defined as a serum HBV DNA level >2,000 IU/mL at any time after NA discontinuation, whereas biochemical relapse was defined as an increase in serum ALT to >2× the upper limit of normal. Clinical relapse was defined as the concomitant occurrence of virological and biochemical relapse. TDF, entecavir (ETV), or tenofovir alafenamide (TAF) was immediately recommended at the physician’s discretion in cases of clinical relapse.
Follow-up
Patients were regularly seen in an outpatient clinic. Laboratory tests were performed during this period. Serum ALT and HBV DNA levels were serially monitored on the 3rd, 7th, 14th, 28th, 56th days in the discontinuation group, and every three months in both groups.
Statistical Analysis
To minimize confounding factors introduced by the retrospective, and nonrandomized design, 1:1 propensity score matching was performed by age and gender. The propensity score without replacement was calculated with a binary logistic regression for each patient. For the matching process, the tolerance for the score in matching cases and controls was set at 0.01. A control is eligible to match a case if the absolute value of the difference in the propensity scores is less than or equal to 0.01. Descriptive statistics are summarized as counts and percentages for categorical variables, mean and standard deviations for normally distributed continuous variables, and median and interquartile range for ordinal and non-normally distributed continuous variables. The differences in proportions between groups were compared using the Chi-Square, Fisher’s Exact tests or Fisher-Freeman-Halton Exact Test, where appropriate. The Mann-Whitney U test was used to compare two groups regarding ordinal or non-normally distributed continuous variables. The survival estimations were performed using the Kaplan-Meier algorithm, and the comparison between groups was evaluated with the Log-rank test. Variables with a p-value <0.25 in the univariable Firth penalized Cox proportional hazards regression were considered candidates for the multivariable Firth penalized Cox model. Variables of established clinical importance were also included, irrespective of their univariable significance, using a purposeful selection approach. The final model was constructed using variables with a p-value less than 0.05, which were considered statistically significant. The hazard ratio (HR) and the associated 95% confidence interval (CI) were calculated. Statistical analyses were performed using IBM SPSS Statistics version 30.0 (IBM Corp., Armonk, NY, USA). A two-tailed P-value less than 0.05 was considered statistically significant.
Results
A total of 146 non-cirrhotic patients with HBeAg-negative CHB were included in the analysis: 73 patients in the NA discontinuation group and 73 in the NA continuation group. The median age of the patients was 52.5 years, and the majority of patients were male (56%). There were no significant differences in baseline characteristics among patients, except that the histological activity index (HAI) was higher in the NA discontinuation group (p<0.001), (Table 1). The median duration of NA therapy before discontinuation was 93 months (IQR: 72–120). The median follow-up duration after NA discontinuation was 44 months (IQR: 25-89).
Table 1.
Characteristics of the matched study cohort
| Characteristic | Overall (n=146) | NA discontinuation (n=73) | NA continuation (n=73) | p |
|---|---|---|---|---|
| Age at the index date (years) | 52.5 (44–59) | 53 (44–59) | 52 (45–59) | 0.943 |
| Sex, male/female (%) | 56/44 | 56/44 | 56/44 | 1.000 |
| Disease duration at the index date (months) | 205.0 (160–229) | 205.0 (176–225) | 205.0 (138–232) | 0.707 |
| Serum HBV DNA (log10 IU/mL) | 5.38 (4.28–6.74) | 5.37 (4.0–6.7) | 5.38 (4.7–6.8) | 0.405 |
| Serum ALT (U/L) | 56 (24–113) | 48 (23–117) | 57.5 (27–112) | 0.592 |
| Serum AST (U/L) | 35 (23–62) | 33 (22–81) | 35 (25–53) | 0.948 |
| Serum GGT (U/L) | 23 (16–35) | 22 (15–35) | 24 (16–34) | 0.576 |
| Total bilirubin (mg/dL) | 0.75 (0.53–1.0) | 0.7 (0.5–1.1) | 0.8 (0.6–1.0) | 0.892 |
| Albumin (g/dL) | 4.3 (4.1–4.5) | 4.3 (4.1–4.5) | 4.3 (4.1–4.5) | 0.821 |
| Platelet count (×103/µL) | 220 (183–269) | 218 (184–277) | 221 (183–264) | 0.601 |
| INR | 1.0 (0.96–1.0) | 1.0 (0.97–1.0) | 1.0 (1.0–1.1) | 0.506 |
| HAI on liver biopsy | 7 (5.5–9.0) | 8 (6.0–9.0) | 6.0 (5–8) | <0.001 |
| Fibrosis score | 1 (1–2) | 1 (1–2) | 2 (1–2) | 0.122 |
| NA treatment at the index date, n | 27 ETV 105 TDF 14 other |
12 ETV 50 TDF 11 other |
15 ETV 55 TDF 3 other |
0.0764 |
Data are presented as median (25th–75th percentiles), percentage, or count, as appropriate. Laboratory and histological variables are pretreatment values obtained before NA initiation; age and disease duration were assessed at the index date. The index date was the date of NA discontinuation for the discontinuation group and the matched cohort-entry date for the continuation group. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CHB: Chronic hepatitis B; ETV: Entecavir; GGT: Gamma-glutamyl transferase; HAI: Histological activity index; HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus; INR: International normalized ratio; NA: Nucleos(t)ide analogue; TDF: Tenofovir disoproxil fumarate. Other NAs included lamivudine and telbivudine.
HBsAg seroclearance was observed in eight patients in the NA discontinuation group, compared to none in the treatment continuation group (p=0.004). HBsAg seroclearance occurred progressively over time. The cumulative probability of HBsAg seroclearance, estimated using the Kaplan–Meier method, reached 16.9% at 120 months (Fig. 2). The median time to HBsAg seroclearance after NA discontinuation was 4.5 months (range, 1 to 81 months). There were no significant differences in baseline characteristics between patients with and without HBsAg seroclearance (Table 2). Firth-penalized Cox regression analysis revealed that only younger age (<50 years) at treatment discontinuation (hazard ratio [HR], 5.72; 95% confidence interval [CI], 1.26–35.01; p=0.023) and elevated baseline AST levels (HR, 6.29; 95% CI, 1.36–39.96; p=0.018) were independently associated with HBsAg seroclearance in patients with CHB (Table 3). Six (75%) patients experienced HBsAg seroconversion to anti-HBs.
Figure 2.

Kaplan–Meier curves illustrating the cumulative probability of HBsAg seroclearance in the nucleos(t)ide analogue discontinuation and continuation groups.
Table 2.
Characteristics of patients with and without HBsAg seroclearance in the NA discontinuation group
| Characteristic | HBsAg seroclearance (n=8) | No HBsAg seroclearance (n=65) | p |
|---|---|---|---|
| Age at the index date (years) | 48 (46–55) | 53 (44–59) | 0.572 |
| Sex, male/female | 7/1 | 34/31 | 0.072 |
| Disease duration at the index date (months) | 197.5 (168.5–212) | 205 (176–228) | 0.270 |
| Serum HBV DNA (log10 IU/mL) | 4.94 (3.67–6.20) | 5.40 (4.00–6.80) | 0.310 |
| Serum HBV DNA >20,000 IU/mL (%) | 57.1 | 69.0 | 0.672 |
| Serum ALT (U/L) | 94 (25–258) | 37.5 (23–109) | 0.270 |
| Serum AST (U/L) | 55 (29–124) | 30 (22–74) | 0.203 |
| Serum GGT (U/L) | 28 (20–56) | 22 (14–32) | 0.167 |
| Total bilirubin (mg/dL) | 0.70 (0.40–1.20) | 0.80 (0.50–1.10) | 0.773 |
| Albumin (g/dL) | 4.20 (3.90–4.30) | 4.40 (4.20–4.60) | 0.069 |
| Platelet count (×103/µL) | 188 (136–269) | 221 (188–277) | 0.186 |
| INR | 1.00 (1.00–1.10) | 1.00 (0.96–1.03) | 0.152 |
| HAI on liver biopsy | 8.50 (8–9) | 8.00 (6–9) | 0.351 |
| Fibrosis score | 1.00 (0–2.00) | 1.00 (1.00–2.00) | 0.700 |
| Significant fibrosis (stage ≥2) (%) | 20 | 36.5 | 0.647 |
Percentages for significant fibrosis (stage ≥2) were calculated among patients with available pretreatment liver biopsy data on fibrosis stage. Data are presented as median (25th–75th percentiles) or percentage, as appropriate. Laboratory and histological variables are pretreatment values obtained before NA initiation; age and disease duration were assessed at the index date, defined as the date of NA discontinuation. Percentages were calculated among patients with available data; denominators may vary because of missing values. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CHB: Chronic hepatitis B; GGT: Gamma-glutamyl transferase; HAI: Histological activity index; HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus; INR: International normalized ratio; NA: Nucleos(t)ide analogue.
Table 3.
Firth-penalized Cox regression analysis of HBsAg seroclearance after NA discontinuation in patients with CHB
| Variable | Univariable HR (95% CI) | p | Multivariable HR (95% CI) | p |
|---|---|---|---|---|
| Age at NA discontinuation, <50 | 2.53 (0.67–10.97) | 0.170 | 5.72 (1.26–35.01) | 0.023 |
| Sex, male vs female | 3.94 (0.86–37.39) | 0.081 | ||
| ALT ≥40 | 3.23 (0.73–19.07) | 0.125 | ||
| AST ≥40 | 4.12 (0.96–23.53) | 0.056 | 6.29 (1.36–39.96) | 0.018 |
| GGT ≥50 | 3.14 (0.56–13.32) | 0.173 | ||
| HBV DNA, <20,000 | 1.40 (0.31–5.87) | 0.647 | ||
| Liver fibrosis stage, <2 | 1.18 (0.26–6.80) | 0.832 | ||
| HBsAg level at NA discontinuation, <1,000 IU/mL | 2.60 (0.57–15.16) | 0.220 |
Reference ranges: ALT and AST, 0–40 U/L; GGT, 10–50 U/L. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CHB: Chronic hepatitis B; CI: Confidence interval; GGT: Gamma-glutamyl transferase; HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus; HR: Hazard ratio; NA: Nucleos(t)ide analogue.
After NA discontinuation, 67% of patients (49/73) in the treatment-discontinuation group experienced virological relapse. Virological relapse was first detected in 19 patients during the first month, 15 during the second month, 5 during the third month, 2 during the fourth month, 4 during the fifth month, and 4 during the sixth month. Virological relapse did not occur in the remaining 24 patients. Of these patients with virological relapse, 29 developed clinical relapses. Most clinical relapses (72%) occurred within the first 3 months after treatment discontinuation. The median time from NA discontinuation to relapse was 2 months (range, 1–60 months). Of these patients, nine had ALT levels >3×ULN, seven had levels >5×ULN, and six had levels >10×ULN. None of these patients had a serum bilirubin level >2 mg/dL. All 29 patients with clinical relapse were successfully retreated with NAs and achieved virological and biochemical responses within a median of 10.5 weeks after retreatment. Overall, 44 patients in the treatment-discontinuation group (60%) did not require retreatment during follow-up. No patient in this group developed cirrhosis or HCC or required hospitalization. There was no significant difference in patient characteristics between patients with and without clinical relapse (Table 4).
Table 4.
Characteristics of patients with and without clinical relapse after NA discontinuation
| Characteristic | Clinical relapse (n=29) | No clinical relapse (n=44) | p |
|---|---|---|---|
| Age ≥50 years at NA discontinuation (%) | 62.1 | 54.5 | 0.525 |
| Male sex (%) | 58.6 | 54.5 | 0.731 |
| Pretreatment serum HBV DNA >20,000 IU/mL (%) | 67.9 | 67.6 | 0.980 |
| Pretreatment serum ALT ≥40 U/L (%) | 48.3 | 52.5 | 0.729 |
| Pretreatment serum AST ≥40 U/L (%) | 41.4 | 42.5 | 0.926 |
| Pretreatment serum GGT ≥50 U/L (%) | 13.8 | 15.0 | 1.000 |
| Significant fibrosis on pretreatment liver biopsy (stage ≥2) (%) | 37.5 | 33.3 | 0.784 |
| HBsAg seroclearance, n (%) | 0 (0) | 8 (18.2) | 0.019 |
Percentages for significant fibrosis (stage ≥2) were calculated among patients with available pretreatment liver biopsy data on fibrosis stage. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CHB: Chronic hepatitis B; GGT: Gamma-glutamyl transferase; HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus; NA: Nucleos(t)ide analogue.
Quantitative HBsAg measurements at the time of NA discontinuation were available for 60 patients. No clinical relapse was observed in patients with HBsAg levels <100 IU/mL (0/5), whereas relapse occurred in 52.2% (12/23) of patients with HBsAg levels between 100 and <1000 IU/mL and in 46.9% (15/32) of those with HBsAg levels ≥1000 IU/mL (p=0.228) (Table 5).
Table 5.
Clinical relapse rates according to quantitative HBsAg level at NA discontinuation
| Quantitative HBsAg Titer (IU/ml) | ||||
|---|---|---|---|---|
| Outcome | <100 IU/mL (n=5) | 100 to <1,000 IU/mL (n=23) | ≥1,000 IU/ mL (n=32) | p |
| Clinical relapse rate, % (n/N) | 0.0 (0/5) | 52.2 (12/23) | 46.9 (15/32) | 0.228 |
The analysis included 60 patients with available quantitative HBsAg measurements at NA discontinuation. HbsAg: Hepatitis B surface antigen; NA: Nucleos(t)ide analogue.
Discussion
In the present study, we evaluated the long-term clinical outcomes of CHB following the discontinuation of NA treatment in patients with HBeAg-negative chronic hepatitis B. These patients had been treated with NA for at least five years and had achieved HBV suppression for at least the last three years preceding discontinuation. In this study, the cumulative HBsAg seroclearance rate among patients who discontinued NA treatment was 16.9% at month 120, with three-quarters of those who achieved HBsAg seroclearance also seroconverting to anti-HBs. However, none of the patients who continued NA treatment had HBsAg seroclearance. This finding confirms that previous studies have shown higher HBsAg seroclearance rates following NA cessation.[12,17–19] It also indicates that discontinuing long-term NA treatment can successfully lead to a functional cure in HBeAg-negative patients with CHB.
HBsAg seroclearance can occur spontaneously in individuals with chronic HBV infections over time. HBsAg seroclearance is associated with sustained immune control of HBV and better clinical outcomes. [7,10,11] Several factors, including age, gender, serum HBsAg and HBV DNA levels, HBeAg status, disease stage, the presence of hepatic steatosis, type and duration of NA therapy, and HBsAg levels at the time of NA discontinuation, affected HBsAg seroclearance.[7,10,11] We recently reported that hepatic steatosis, as documented by liver biopsy, contributes to HBsAg seroclearance in patients with chronic HBV infection.[20] Serum AST level appeared to be a more robust immunologic indicator than serum ALT level and possibly reflects greater immune-mediated hepatocellular activity relevant to functional cure.[21] In the present study, younger age and elevated pretreatment serum AST levels were significantly associated with achieving a functional cure, and this association increased over time. Additionally, nearly all patients who achieved a functional cure had low serum HBsAg levels at the time of discontinuation of NA treatment.
The immune control network of HBV infection is a complex interplay between HBV and host immunity. There is a consensus regarding the relationship between adaptive immune responses and HBV-specific T-cell responses. Multispecific and robust HBV-specific T cells play a significant role in managing HBV infection by directly killing HBV-infected hepatocytes and through non-cytolytic degradation of HBV markers, such as cccDNA, during a self-limiting acute HBV infection. [21–23] However, HBV-specific T cell responses are often hardly detectable and non-functional in patients with CHB due to chronic antigenic overstimulation of these T cells.[21] This phenomenon is referred to as T-cell exhaustion. NA treatment can help recover T cell responses.[18,21,24,25] The extent of virological or biochemical relapse after discontinuation of NA treatment is a key factor in triggering the immune system and achieving a functional cure.[18,21,24,25]
Virological relapse induces the production of inflammatory and antiviral cytokines, chemokines, and growth factors.[18,21,24,25] This altered cytokine milieu, along with an increased amount of HBV antigens, may act as activators of the immune response against HBV. A maximum peak level of serum HBV DNA during virological relapse and an increase in serum ALT levels are associated with subsequent HBsAg seroclearance.[18] Furthermore, after discontinuation of NA treatment, virological relapse may induce multifunctional T-cell responses in patients with CHB. Clinical relapse has therefore been proposed as a potential trigger for immune control.[18]
HBV-specific T cell responses were heterogeneous among patients with CHB. In addition to a functional cure, most patients who discontinued NA treatment achieved sustained remission after stopping treatment.[7,8] These patients had negative or low HBV DNA levels (<2000 IU/mL) and normal serum ALT levels during the follow-up period, similar to those with chronic HBV infection.
The timing of retreatment with NA in patients with clinical relapse is unclear. After the discontinuation of NA treatment, serum HBV DNA levels increased immediately. Most clinical relapse cases occurred within the first three months following treatment discontinuation, consistent with previous reports.[8,12] A virological relapse should be considered a precursor to a biochemical relapse. Notably, only half of these spikes were accompanied by serum aminotransferase elevations exceeding twice the upper limit of normal. These findings support structured monitoring after NA discontinuation, particularly during the first 24 weeks, when the risk of reactivation is highest. In the subsequent assessments conducted during the first six months after discontinuing treatment, we observed 49 virological relapses. Importantly, clinical relapses in these 29 patients were reliably controlled with NAs and responded favorably to retreatment. No serious adverse events were observed following NA retreatment.
This study involved a well-defined and homogeneous CHB patient population, with long-term follow-up and comparison to an age- and sex-matched control group. There are a few limitations that should be acknowledged. This study employed a retrospective single-center design, which may limit the generalizability of our findings. Propensity-score matching was based solely on age and sex. Additionally, quantitative HBsAg levels measured using the Roche Elecsys HBsAg II kit were not routinely available in clinical practice, hindering a more detailed analysis of virological dynamics.
Conclusion
In conclusion, the discontinuation of long-term NA treatment for non-cirrhotic, HBeAg-negative CHB patients represents a promising strategy toward achieving a functional cure. Younger age and elevated baseline serum aminotransferase levels appear to be strong indicators of a potential functional cure. Ensuring close post-discontinuation surveillance remains essential to promptly manage clinical relapses.
Footnotes
How to cite this article: Melekoglu Ellik Z, Sah Unal FT, Koc O, Tunc E, Yilmaz V, Bodakci E, et al. Hepatitis B surface antigen seroclearance after nucleos(t)ide analogue discontinuation innon-cirrhotic patients with chronic hepatitis B. Hepatology Forum 2026; 7(4):337–344.
Ethics Committee Approval
The study protocol was approved by the Ankara University Faculty of Medicine Human Research Ethics Committee (dated May 22, 2025, and numbered 2025/393), and the study was conducted in accordance with the principles of the Declaration of Helsinki.
Informed Consent
Written informed consents were obtained from patients who participated in this study.
Conflict of Interest
The authors did not have any conflicts of interest to declare.
Financial Disclosure
The authors declared that this study has received no financial support.
Use of AI for Writing Assistance
The authors did not use artificial intelligence (AI)-assisted technologies, including large language models, chatbots, or AI-generated image tools, in the preparation of this manuscript.
Author Contributions
Concept: ZME, FTSU, HG, CY, RI; Design: ZME, FTSU, AHE, BS, HG, CY, RI; Materials: OK, VY, EB, MG, MO, HG, RI; Data Collection and/or Processing: ZME, FTSU, OK, ET, EB, MO, REE, SK, BS, RI; Analysis and/or Interpretation: ET, AHE, RI; Literature Search: ZME, RI, CY, HG; Writing: ZME, RI; Critical Review: ZME, HG, RI.
Peer-review
Externally peer-reviewed.
References
- 1.World Health Organization . Geneva: 2024. Hepatitis B [Internet] [cited 2025 Oct 21]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. [Google Scholar]
- 2.Polaris Observatory Collaborators Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403. doi: 10.1016/S2468-1253(18)30056-6. [DOI] [PubMed] [Google Scholar]
- 3.Idilman R, Aydogan M, Oruncu MB, Kartal A, Elhan AH, Ellik Z, et al. Natural history of cirrhosis: changing trends in etiology over the years. Dig Dis. 2021;39(4):358–365. doi: 10.1159/000512746. [DOI] [PubMed] [Google Scholar]
- 4.Üçbilek E, Yıldırım AE, Ellik Z, Turan İ, Haktanıyan B, Orucu B, et al. Changing trends in the etiology of cirrhosis in türkiye: a multicenter nationwide study. Turk J Gastroenterol. 2024;35(10):772–777. doi: 10.5152/tjg.2024.23572. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Guzelbulut F, Karaogullarindan U, Akkiz H, Altintas E, Demirtas CO, Bahadir O, et al. Characteristics of patients with hepatocellular carcinoma: A multicenter study. Hepatol Forum. 2022;3(3):71–76. doi: 10.14744/hf.2022.2022.0028. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21(11):1020–1026. doi: 10.1016/j.cmi.2015.06.028. [DOI] [PubMed] [Google Scholar]
- 7.European Association for the Study of the Liver EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi: 10.1016/j.jhep.2017.03.021. [DOI] [PubMed] [Google Scholar]
- 8.van Bömmel F, Berg T. Risks and benefits of discontinuation of nucleos(t)ide analogue treatment: a treatment concept for patients with HBeAg-negative chronic hepatitis B. Hepatol Commun. 2021;5(10):1632–1648. doi: 10.1002/hep4.1708. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Marcellin P, Gane EJ, Flisiak R, Trinh HN, Petersen J, Gurel S, et al. Long term treatment with tenofovir disoproxil fumarate for chronic hepatitis b infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8 year results from two phase 3 trials: 229. Hepatology. 2014;60:313A–314A. [Google Scholar]
- 10.European Association for the Study of the Liver EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025;83(2):502–583. doi: 10.1016/j.jhep.2025.03.018. [DOI] [PubMed] [Google Scholar]
- 11.Maung ST, Decharatanachart P, Chaiteerakij R. Hepatitis B surface antigen seroclearance rate after stopping nucleos(t)ide analogues in chronic hepatitis B-a systematic review and meta-analysis. J Gastroenterol Hepatol. 2025;40(5):1079–1104. doi: 10.1111/jgh.16920. [DOI] [PubMed] [Google Scholar]
- 12.van Bömmel F, Stein K, Heyne R, Petersen J, Buggisch P, Berg C, et al. A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B. J Hepatol. 2023;78(5):926–936. doi: 10.1016/j.jhep.2022.12.018. [DOI] [PubMed] [Google Scholar]
- 13.Berg T, Simon KG, Mauss S, Schott E, Heyne R, Klass DM, et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients-FINITE study. J Hepatol. 2017;67(5):918–924. doi: 10.1016/j.jhep.2017.07.012. [DOI] [PubMed] [Google Scholar]
- 14.Papatheodoridi M, Papachristou E, Moschidis Z, Hadziyannis E, Rigopoulou E, Zachou K, et al. Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy. J Viral Hepat. 2022;29(11):948–957. doi: 10.1111/jvh.13729. [DOI] [PubMed] [Google Scholar]
- 15.Papatheodoridis G, Vlachogiannakos I, Cholongitas E, Wursthorn K, Thomadakis C, Touloumi G, et al. Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. Hepatology. 2016;63(5):1481–1492. doi: 10.1002/hep.28438. [DOI] [PubMed] [Google Scholar]
- 16.Hirode G, Choi HSJ, Chen CH, Su TH, Seto WK, Van Hees S, et al. Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B Study) Gastroenterology. 2022;162(3):757–771.e4. doi: 10.1053/j.gastro.2021.11.002. [DOI] [PubMed] [Google Scholar]
- 17.Kiremitçi S, Koçhan K, Seven G, Biberci Keskin E, Okay G, Akkoyunlu Y, et al. Results of nucleos(t)ide analog treatment discontinuation in hepatitis b e-antigen-negative chronic hepatitis B: NUCSTOP Study. Turk J Gastroenterol. 2024;35(1):17–26. doi: 10.5152/tjg.2024.23463. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Höner Zu Siederdissen C, Rinker F, Maasoumy B, Wiegand SB, Filmann N, Falk CS, et al. Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. J Infect Dis. 2016;214(10):1492–1497. doi: 10.1093/infdis/jiw412. [DOI] [PubMed] [Google Scholar]
- 19.Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology. 2012;143(3):629–636.e1. doi: 10.1053/j.gastro.2012.05.039. [DOI] [PubMed] [Google Scholar]
- 20.Bodakci E, Kiremitci S, Ellik ZM, Koc O, Gumussoy M, Yilmaz V, et al. Hepatic steatosis is associated with HBsAg seroclearance in patients with chronic hepatitis B virus infection but it is also associated with disease progression. Hepatol Forum. 2026;7(1):14–20. doi: 10.14744/hf.2025.74529. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Rinker F, Zimmer CL, Höner Zu Siederdissen C, Manns MP, Kraft ARM, Wedemeyer H, et al. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. J Hepatol. 2018;69(3):584–593. doi: 10.1016/j.jhep.2018.05.004. [DOI] [PubMed] [Google Scholar]
- 22.Xia Y, Stadler D, Lucifora J, Reisinger F, Webb D, Hösel M, et al. Interferon-γ and Tumor Necrosis Factor-α Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis. Gastroenterology. 2016;150(1):194–205. doi: 10.1053/j.gastro.2015.09.026. [DOI] [PubMed] [Google Scholar]
- 23.Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. 2007;81(8):4215–4225. doi: 10.1128/JVI.02844-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Boni C, Laccabue D, Lampertico P, Giuberti T, Viganò M, Schivazappa S, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology. 2012;143(4):963–973.e9. doi: 10.1053/j.gastro.2012.07.014. [DOI] [PubMed] [Google Scholar]
- 25.Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, Missale G, et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol. 2003;39(4):595–605. doi: 10.1016/S0168-8278(03)00292-7. [DOI] [PubMed] [Google Scholar]
